AstraZeneca sees higher 2022 sales, but COVID boost waning
AstraZeneca forecast higher 2022 sales and raised its annual dividend for the first time in a decade, but warned that the boost from COVID-19 products would fall.
Subscribe to:
Post Comments (Atom)
Comments
Post a Comment
Leave a comment. Thanks!
Comentarios de Facebook